quinoxalines has been researched along with posaconazole in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gilbert, M; Laustsen, G; Wimett, L | 1 |
| Abidi, SH; Ali, S; Allemailem, KS; Almansour, NM; Amerzhanov, D; Ibrahim, MAA; la Fleur, P; Lukac, M; Rafaqat, W | 1 |
2 other study(ies) available for quinoxalines and posaconazole
| Article | Year |
|---|---|
Drug approvals.
Topics: Acetanilides; Alprostadil; Angina Pectoris; Benzazepines; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Drug Approval; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Fatty Acids; Herpes Zoster Vaccine; Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; Humans; Ibandronic Acid; Insulin; Lubiprostone; Naltrexone; Narcotic Antagonists; Nurse's Role; Papillomavirus Vaccines; Patient Education as Topic; Piperazines; Quinoxalines; Ranolazine; Triazoles; United States; United States Food and Drug Administration; Varenicline | 2007 |
Repurposing potential of posaconazole and grazoprevir as inhibitors of SARS-CoV-2 helicase.
Topics: Amides; Antiviral Agents; Carbamates; COVID-19 Drug Treatment; Cyclopropanes; Drug Repositioning; Enzyme Inhibitors; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Protein Domains; Quinoxalines; RNA Helicases; SARS-CoV-2; Sulfonamides; Triazoles; Viral Proteins | 2021 |